0001654954-24-009045.txt : 20240717
0001654954-24-009045.hdr.sgml : 20240717
20240717111436
ACCESSION NUMBER: 0001654954-24-009045
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240715
FILED AS OF DATE: 20240717
DATE AS OF CHANGE: 20240717
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DUNTON ALAN W
CENTRAL INDEX KEY: 0001304773
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15543
FILM NUMBER: 241121378
MAIL ADDRESS:
STREET 1: VICURON PHARMACEUTICALS INC
STREET 2: 455 S GULPH ROAD SUITE 305
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PALATIN TECHNOLOGIES INC
CENTRAL INDEX KEY: 0000911216
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 954078884
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 4B CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: 609-495-2200
MAIL ADDRESS:
STREET 1: 4B CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
FORMER COMPANY:
FORMER CONFORMED NAME: INTERFILM INC
DATE OF NAME CHANGE: 19930825
4/A
1
section16.xml
FORM 4
X0508
4/A
2024-07-15
2024-07-16
0000911216
PALATIN TECHNOLOGIES INC
PTN
0001304773
DUNTON ALAN W
PALATIN TECHNOLOGIES, INC.
4B CEDAR BROOK DRIVE
CRANBURY
NJ
08512
true
false
false
false
false
Common Stock
2024-07-15
4
A
false
12000
0
A
42294
D
Stock Option (Right to Buy)
1.83
2024-07-15
4
A
false
17000
0
A
2025-06-04
2034-06-04
Common Stock
17000
57780
D
Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 4, 2025. The restricted share units were granted by the Compensation Committee on June 4, 2024, which grant was subject to certification by the Chief Financial Officer that the shareholders had increased the shares reserved under the 2011 Stock Incentive Plan, and that there were no impediments to the grant of the options. The required certification was made on July 15, 2024.
The option vests on June 4, 2025, and in the event that the director does not serve until June 30, 2025, is prorated based on the period of service at the rate of 1/12 per month on the last day of each month, starting on July 31, 2024. The options were granted by the Compensation Committee on June 4, 2024, which grant was subject to certification by the Chief Financial Officer that the shareholders had increased the shares reserved under the 2011 Stock Incentive Plan, and that there were no impediments to the grant of the options. The required certification was made on July 15, 2024.
This amendment corrects an error in Table II, column 2, to correct the conversion or exercise price of the derivative security to $1.83. There are no other changes.
/s/ Alan W. Dunton, by Stephen A. Slusher, Attorney-in-Fact
2024-07-17